For the estimated 3.4 million people in the United States with Alzheimer’s disease (AD), approved pharmacotherapy is limited to four procognitive symptomatic agents (e.g., donepezil, memantine) that deliver modest efficacy of limited duration. Understanding today’s treatment landscape is important for emerging players as the heavily generic AD therapy market prepares for the potential entry of new, high-cost brands—namely, landmark disease-modifying therapies and new behavioral adjuncts. Our Treatment Algorithms: Claims Data Analysis content provides national patient-level claims data to explore the use of key therapies in both newly diagnosed and recently treated patients.
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed AD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed AD patients?
- What is the dynamic between memantine formulations now that both are generic? How has Namzaric been integrated into the treatment algorithm, and what is its source of business?
- What percentage of AD patients receive drug therapy within two years of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within two years of diagnosis?
- What percentage of AD patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients with AD?
Geographies: United States
Real World data: Longitudinal patient-level claims data analysis
Key Drugs Covered: Donepezil, galantamine, rivastigmine, rivastigmine patch, memantine IR, Namenda XR, Namzaric, antipsychotics, antidepressants
Key Analysis provided:
- Brand/therapy usage across longitudinal patient sample
- Newly diagnosed patient analysis
- Treatment initiation and progression
- Line of therapy analysis
- Combination therapy analysis
- Source of business for recently treated patients
- Persistency and compliance analysis
- Product-level patient flowcharts
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
- Alzheimer's Disease - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)
- Treatment Algorithms CDA Alzheimer's Disease US April 2020
Author(s): Jonathan Searles
Jonathan W. Searles is a Senior Director in the CNS/Ophthalmology unit at DRG, overseeing the neurology research stream. Prior to joining DRG, Mr. Searles received a B.A. degree, summa cum laude, from Brandeis University; during this time, Mr. Searles conducted research projects at the Harvard University Peabody Museum and at Brandeis.